

The COVID-19 emerging variant first detected in the United Kingdom called B.1.1.7. According to scientific research reports, this emerging variant virus has a 50-75% increase in infectivity than other virus strains¹. The virus has acquired 23 mutations all at once that change the virus' proteins, which affect particularly in Spike protein (HV 69-70 deletion, Y 144 deletion, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H) and other mutations².

AllBio's COVID-19 rapid test kit uses full-length recombinant protein, including the Nucleocapsid protein (N-protein) and Spike protein (S-protein) single-point mutation will not change the protein folding configuration, so It will not affect the identification results of AllBio's COVID-19 rapid test kit.

So, we hereby declare that the following COVID-19 rapid test kit developed by AllBio still valid effectively detects infections caused by the COVID-19 variant virus B.1.1.7. This variant virus will not affect the detection performance of our products below.

(a) COVID19 IgG & IgM Antibody Detection Kit (Colloidal Gold Method) For in vitro diagnosis (Cat. No: ABCOVIDGM1901)

(b) COVID19 Ag Rapid Test Kit (Cat. No: ABCOVID19AG01)

1. Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England. doi: <http://doi.org/10.1101/2020.12.24.20248822>
2. Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro Surveill. 2021 Jan;26(1). doi: 10.2807/1560-7917.ES.2020.26.1.2002106.

AllBio Science, Inc.

2021.01.13

